34
PERGUNTAS & RESPOSTAS
RETINOPATIA DIABÉTICA - Novo Paradigma de Cuidados
Anti-agregantes plaquetários: Apesar de existir um racional para
sustentar o seu efeito benéfico na ciência básica, nenhum estudo
clínico (de fase II ou III) conseguiu até à presente data demonstrar a
sua importância
26
.
Estatinas: O seu efeito benéfico não está completamente demons-
trado
13
.
Tiazolidinedionas (glitazonas): Uma chamada de atenção para
estes antidiabéticos orais que
induzem e agravam o edema macular
diabético
27,28
.
Um estudo prospetivo com 170.000 doentes diabéti-
cos demonstrou a associação entre o uso destas drogas e o edema
macular diabético com um Odds Ratio de 2,6 (95% CI 2,4-3,0)
29
.
Bibliografia
1.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The wisconsin epidemio-
logic study of diabetic retinopathy: XVII. The 14-year incidence and
progression of diabetic retinopathy and associated risk factors in type 1
diabetes. Ophthalmology. 1998;105:1801-15.
2.
The relationship of glycemic exposure (HbA1c) to the risk of development
and progression of retinopathy in the diabetes control and complications
trial. Diabetes. 1995;44:968-83.
3.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The wisconsin epidemiolo-
gic study of diabetic retinopathy. XIV. Ten-year incidence and progression
of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217-28.
4.
Klein R, Klein BE, Moss SE, Davis MD, Demets DL. The wisconsin epide-
miologic study of diabetic retinopathy. III. Prevalence and risk of diabetic
retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol.
1984;102: 527-32
5.
Diabetes Control and Complications Trial Research Group. The effect of
intensive diabetes treatment on the progression of diabetic retinopathy in
insulin-dependent diabetes mellitus. Arch Ophthalmol.1995;113:36-51.
6.
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro-
vascular and microvascular complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ. 2000;321:405-12.
7.
ADVANCE Management Committee Study rationale and design of
ADVANCE: Action in Diabetes and Vascular disease: preterax and diami-
cron MR controlled evaluation. Diabetologia 2001; 44: 1118– 1120.
8.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM,
et al. Intensive glycemic control and the prevention of cardiovascular
events: implications of the ACCORD, ADVANCE, and VA diabetes trials:
a position statement of the American Diabetes Association and a scienti-
fic statement of the American College of Cardiology Foundation and the